Defendant

Optiver Trading US LLC

2 cases as defendant.

Cases
2
Active
2
0 closed
Filed
2025
Top venue
W.D. Texas
2 cases

Company profile

Optiver Trading US LLC is the U.S. entity of Optiver, a privately owned global proprietary trading firm and market maker founded in Amsterdam, Netherlands, in 1986. The company's U.S. headquarters are located in Chicago, Illinois, with an additional U.S. office in Austin, Texas. Globally, Optiver employs over 2,100 professionals across 11 offices and reported a revenue of approximately €3.5 billion in 2024.

Optiver operates as an active trading firm, specializing in market making and proprietary trading across a wide array of financial instruments. Its core activities include providing liquidity and competitive pricing in equities, options, futures, exchange-traded funds (ETFs), bonds, and foreign exchange markets. The firm leverages advanced technology and quantitative research to develop sophisticated trading algorithms and systems to enhance market efficiency, transparency, and stability.

In terms of patent litigation, Optiver Trading US LLC appears as a defendant in its single tracked case, with no instances as a plaintiff. This posture suggests that Optiver Trading US LLC is an operating company that defends against patent infringement claims, rather than a patent assertion entity.

The company's sole tracked litigation, HFT Solutions LLC v. Optiver US LLC et al., is currently ongoing in the United States District Court for the Western District of Texas. The plaintiff's name, HFT Solutions LLC, implies a focus on high-frequency trading technology, which aligns with Optiver's core business operations.

HFT Solutions, LLC v. Optiver US LLC et al.

Active, trial scheduled
Docket:
7:25-cv-00415
Filed:
2025-09-08
Patents:11329655

HFT Solutions, LLC commenced this patent infringement lawsuit alleging infringement of patents within its High-Frequency Trading (HFT) Patent Portfolio, including US Patent 11329655. Defendants Optiver US LLC and Optiver Trading US LLC filed counterclaims of non-infringement and invalidity. A trial date is scheduled for June 7, 2027.